Biofrontera Stock Drops 6% Despite Securing FDA Approval For Ameluz SNDA

Biofrontera announced FDA approval of its supplemental New Drug Application for Ameluz topical gel 10% used with photodynamic therapy via the BF-RhodoLED lamp series for treatment of superficial skin lesions. The approval expands the regulatory profile and potential commercial opportunity for Biofrontera's dermatology treatment platform, representing a meaningful positive catalyst for BFRI.